
Radio and PodcastLive Radio & Podcasts
109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results
Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma and DLBCL. Selinexor blocks nuclear export thereby hindering the ability of cancer cells to block tumor suppressor protein...
About This Episode
109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results is an episode from Breaking Biotech by Matthew Lepoire. Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myel...
This episode belongs to Breaking Biotech.
Use the player on this page to stream the episode online.
Published Feb 22, 2022, 00:33:42 long, audio available.
Questions About This Episode
What is 109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results about?
Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma and DLBCL. Selinexor blocks nuclear export thereby hindering the ability of cancer cells to block tumor suppressor protein activity. In this episode, I break down the bear and bull narratives of Karyopharm and discuss how the company has transitioned since entry of the new CEO Richard Paulson. Thanks to InfoPathways for being a sponsor of the show! Check them out for all your biotech IT needs at infopathways.com or call 410-751-9929. Help out the show (or join the discord) by becoming a patron at: Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt (nor his guests) cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt (nor his guests) is/are not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt (nor his guests) does/do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.
Where can I listen to 109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results?
You can listen to 109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is 109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results from?
109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results is an episode from Breaking Biotech by Matthew Lepoire.
How long is this episode?
This episode is 00:33:42 long.
When was this episode published?
This episode was published on Feb 22, 2022.
Can I save 109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from Breaking Biotech?
Yes. This page shows related episodes from Breaking Biotech when more episodes are available from the podcast feed.
Quick Answers About This Episode
Where can I listen to 109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results?
You can listen to 109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results on this page when the episode audio is available from the podcast feed.
Which podcast is this episode from?
109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results is from Breaking Biotech by Matthew Lepoire.
What are the episode details?
Published Feb 22, 2022 and 00:33:42 long